Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

What’s ahead for the Life Sciences industry?

Posted on December 30th, 2019 by in Pharma R&D

As the year comes to a close, we’re thinking about trends in the landscape and where the industry is headed. What do some of the members of Elsevier’s Life Sciences team think?

Tom Pianko VP of Global Key Accounts, counts machine learning, artificial intelligence, data normalization and advance analytics tools among the trends that point to where the Life Sciences industry is going—and many of his colleagues agree.

(more…)

‘Tis the season to have your own pharma-themed film festival

Posted on December 23rd, 2019 by in Pharma R&D

The warmest family celebration of the year is almost here! All my friends and colleagues around me have started thinking about the best ways to spend this year’s family gathering. Well, if you are like me—a geeky introvert who enjoys time alone—nothing goes better with family parties and eating huge amounts of food than relaxing on the couch and binge-watching movies and TV shows.

(more…)

Global Dominance in AI? China’s Got a Plan For That

Posted on July 9th, 2019 by in Pharma R&D

Artificial intelligence is more than just a ‘hot topic’ in the pharmaceutical industry—it is actually influencing the way that major industry players and even entire nations are thinking about the future. As more AI-focused companies are launching, and as investment in AI technology is increasing in the US and EU, China is speeding up its efforts to ensure that it can be competitive in this burgeoning area.

(more…)

How Drug Repurposing Is Revitalizing the Pharma Industry

Posted on October 16th, 2018 by in Pharma R&D

The average expense of bringing a new drug to market has increased by more than 200 percent since the 1990s, with development costs regularly running into the billions. As pharma revenues continue to sink below the costs of creating commercially viable drugs, a growing number of developers are exploring a different approach: seeking out additional monetizable uses for drugs to which they already own intellectual property rights. (more…)

  1. 1
  2. 2
  3. 3
  4. 4
  5. 11